orourke
News Release

FDA Approves Personalized Cellular Therapy for Advanced Leukemia

In a landmark decision for the field of cancer immunotherapy, the U.S. Food and Drug Administration today approved a personalized cellular therapy developed by the University of Pennsylvania and Children’s Hospital of Philadelphia for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

On the News Blog

Penn Medicine In the News

  • What’s the Best Way to Take an Afternoon Nap?

    September 19, 2017
  • With $1.4 Million, Penn Scientist to Study Why Brain Cells Can’t Get Rid of ‘Trash’

    September 19, 2017
  • Penn Doctor Raising Money for Alzheimer’s Research Through 5K Race/Walk

    September 19, 2017
  • Solving Clinical Challenges in Major Depression

    September 19, 2017
  • “Make the Best of It Bash” Donates $500,000 to Penn Medicine Melanoma Research

    September 19, 2017
  • Looking Back, Looking Forward, and Looking Up

    September 19, 2017